Preclinical models based on genetic mutations associated with the familial form of Parkinson's disease

Author(s):  
Juan Segura-Aguilar
Life ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 371
Author(s):  
Filipa Barroso Gonçalves ◽  
Vanessa Alexandra Morais

Mitochondria are known as highly dynamic organelles essential for energy production. Intriguingly, in the recent years, mitochondria have revealed the ability to maintain cell homeostasis and ultimately regulate cell fate. This regulation is achieved by evoking mitochondrial quality control pathways that are capable of sensing the overall status of the cellular environment. In a first instance, actions to maintain a robust pool of mitochondria take place; however, if unsuccessful, measures that lead to overall cell death occur. One of the central key players of these mitochondrial quality control pathways is PINK1 (PTEN-induce putative kinase), a mitochondrial targeted kinase. PINK1 is known to interact with several substrates to regulate mitochondrial functions, and not only is responsible for triggering mitochondrial clearance via mitophagy, but also participates in maintenance of mitochondrial functions and homeostasis, under healthy conditions. Moreover, PINK1 has been associated with the familial form of Parkinson’s disease (PD). Growing evidence has strongly linked mitochondrial homeostasis to the central nervous system (CNS), a system that is replenished with high energy demanding long-lasting neuronal cells. Moreover, sporadic cases of PD have also revealed mitochondrial impairments. Thus, one could speculate that mitochondrial homeostasis is the common denominator in these two forms of the disease, and PINK1 may play a central role in maintaining mitochondrial homeostasis. In this review, we will discuss the role of PINK1 in the mitochondrial physiology and scrutinize its role in the cascade of PD pathology.


2021 ◽  
pp. 1-6
Author(s):  
Mark Tomishima ◽  
Agnete Kirkeby

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.


2007 ◽  
Vol 28 (11) ◽  
pp. 1709-1717 ◽  
Author(s):  
Haibing Jiang ◽  
Yen-Ching Wu ◽  
Masayuki Nakamura ◽  
Yideng Liang ◽  
Yuji Tanaka ◽  
...  

2019 ◽  
Vol 73 ◽  
pp. 38-46
Author(s):  
Adriana Wawer ◽  
Ilona Joniec-Maciejak ◽  
Anna Sznejder-Pachołek ◽  
Dagmara Mirowska-Guzel

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease of central nervous system. Despite many years of research its pathogenesis remains elusive. The main pathological process observed in PD is the degeneration of dopaminergic neurons in the substantia nigra and the reduction in the concentration of dopamine and its metabolites in the striatum and basal ganglia. In addition, a reduction in the activity of enzymes involved in the synthesis and metabolism of dopamine (e.g. tyrosine hydroxylase) is observed. The process of neurodegeneration is accompanied by the development of inflammatory reaction and the formation of intraneuronal inclusions - Lewy’s bodies, which containing mainly of α‑synuclein (ASN). The presence of ASN in Lewy bodies and the association of mutations in the gene encoding ASN with the familial form of the disease indicates the important role of this protein in the pathogenesis of PD. ASN is a small protein widely distributed in the brain. Under physiological conditions it is involved, among others, in dopamine metabolism. Changes in ASN levels due to its aggregation, overexpression or decreased expression may disrupt dopaminergic system functions and contribute to the neurodegeneration process observed in PD. Our paper is focused on murine ASN-based models of PD. In this review we describe models based on transgenic mice, viral vectors containing the ASN gene, and those in which elevated ASN levels are obtained by intracerebral protein administration. We briefly discuss the advantages of developed models and their numerous limitations We also highlight the need for further search for the ideal disease model.


Author(s):  
Krys S. Bankiewicz ◽  
Rosario Sanchez‐Pernaute ◽  
Yoshitsugu Oiwa ◽  
Malgorzata Kohutnicka ◽  
Alex Cummins ◽  
...  

Author(s):  
Krys S. Bankiewicz ◽  
Rosario Sanchez-Pernaute ◽  
Yoshitsugu Oiwa ◽  
Malgorzata Kohutnicka ◽  
Alex Cummins ◽  
...  

2016 ◽  
Vol 73 (7) ◽  
pp. 1383-1385 ◽  
Author(s):  
Dan Lindholm ◽  
Johanna Mäkelä ◽  
Valentina Di Liberto ◽  
Giuseppa Mudò ◽  
Natale Belluardo ◽  
...  

2011 ◽  
Vol 1413 ◽  
pp. 72-83 ◽  
Author(s):  
Xu Yue ◽  
Torsten Falk ◽  
Leslie A. Zuniga ◽  
Lajos Szabò ◽  
Frank Porreca ◽  
...  

2017 ◽  
Vol 10 (5) ◽  
pp. 633-643 ◽  
Author(s):  
Valentin Evsyukov ◽  
Andrii Domanskyi ◽  
Holger Bierhoff ◽  
Suzana Gispert ◽  
Rasem Mustafa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document